For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
Rigel Pharmaceuticals (NASDAQ: RIGL) closed the day trading at $34.52 up 3.17% from the previous closing price of $33.46. In other words, the price has increased by $3.17 from its previous closing price. On the day, 1.14 million shares were traded. RIGL stock price reached its highest trading level at $35.17 during the session, while it also had its lowest trading level at $33.302.
Ratios:
For a better understanding of RIGL, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.71 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.41. For the most recent quarter (mrq), Quick Ratio is recorded 1.90 and its Current Ratio is at 2.02. In the meantime, Its Debt-to-Equity ratio is 0.75 whereas as Long-Term Debt/Eq ratio is at 0.47.
Piper Sandler Downgraded its Overweight to Neutral on June 08, 2022, whereas the target price for the stock was revised from $7 to $1.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 04 ’25 when Schorno Dean L sold 2,036 shares for $20.92 per share. The transaction valued at 42,595 led to the insider holds 58,969 shares of the business.
Schorno Dean L sold 1,734 shares of RIGL for $38,020 on Feb 05 ’25. The EVP & Chief Financial Officer now owns 57,235 shares after completing the transaction at $21.93 per share. On Feb 04 ’25, another insider, Santos David A, who serves as the EVP, Chief Commercial Officer of the company, sold 2,125 shares for $20.92 each. As a result, the insider received 44,457 and left with 53,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RIGL now has a Market Capitalization of 619195584 and an Enterprise Value of 571861952. As of this moment, Rigel’s Price-to-Earnings (P/E) ratio for their current fiscal year is 6.38, and their Forward P/E ratio for the next fiscal year is 10.78. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.13. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.31 while its Price-to-Book (P/B) ratio in mrq is 7.56. Its current Enterprise Value per Revenue stands at 2.134 whereas that against EBITDA is 5.344.
Stock Price History:
The Beta on a monthly basis for RIGL is 1.19, which has changed by 1.8838763 over the last 52 weeks, in comparison to a change of 0.18157876 over the same period for the S&P500. Over the past 52 weeks, RIGL has reached a high of $33.82, while it has fallen to a 52-week low of $10.28. The 50-Day Moving Average of the stock is 62.93%, while the 200-Day Moving Average is calculated to be 71.28%.
Shares Statistics:
Over the past 3-months, RIGL traded about 296.04K shares per day on average, while over the past 10 days, RIGL traded about 901670 shares per day. A total of 17.94M shares are outstanding, with a floating share count of 17.44M. Insiders hold about 2.79% of the company’s shares, while institutions hold 75.57% stake in the company. Shares short for RIGL as of 1753920000 were 2511219 with a Short Ratio of 8.48, compared to 1751241600 on 2172820. Therefore, it implies a Short% of Shares Outstanding of 2511219 and a Short% of Float of 14.38.
Earnings Estimates
Current recommendations for the stock of the company come from 6.0 analysts. The consensus estimate for the next quarter is $0.67, with high estimates of $1.03 and low estimates of $0.16.
Analysts are recommending an EPS of between $6.02 and $0.93 for the fiscal current year, implying an average EPS of $4.91. EPS for the following year is $3.31, with 6.0 analysts recommending between $5.78 and $1.1.
Revenue Estimates
5 analysts predict $61.88M in revenue for the current quarter. It ranges from a high estimate of $65.6M to a low estimate of $59.1M. As of the current estimate, Rigel Pharmaceuticals’s year-ago sales were $55.31MFor the next quarter, 5 analysts are estimating revenue of $64.77M. There is a high estimate of $69.7M for the next quarter, whereas the lowest estimate is $60.9M.
A total of 5 analysts have provided revenue estimates for RIGL’s current fiscal year. The highest revenue estimate was $290.32M, while the lowest revenue estimate was $275M, resulting in an average revenue estimate of $281.09M. In the same quarter a year ago, actual revenue was $179.28MBased on 6 analysts’ estimates, the company’s revenue will be $270.23M in the next fiscal year. The high estimate is $346.4M and the low estimate is $232.65M.
